Academic Journal
View in EDS
HTML Full Text

Total Metabolic Tumor Volume on 18F-FDG PET/CT Is a Useful Prognostic Biomarker for Patients with Extensive Small-Cell Lung Cancer Undergoing First-Line Chemo-Immunotherapy.

Bibliographic Details
Title: Total Metabolic Tumor Volume on 18F-FDG PET/CT Is a Useful Prognostic Biomarker for Patients with Extensive Small-Cell Lung Cancer Undergoing First-Line Chemo-Immunotherapy.
Authors: Grambow-Velilla, Julia, Seban, Romain-David, Chouahnia, Kader, Assié, Jean-Baptiste, Champion, Laurence, Girard, Nicolas, Bonardel, Gerald, Matton, Lise, Soussan, Michael, Chouaïd, Christos, Duchemann, Boris
Source: Cancers; Apr2023, Vol. 15 Issue 8, p2223, 14p
Subject Terms: LUNG cancer, CONFIDENCE intervals, CANCER chemotherapy, ANTINEOPLASTIC agents, RETROSPECTIVE studies, ACQUISITION of data, CANCER patients, TREATMENT effectiveness, RADIOPHARMACEUTICALS, POSITRON emission tomography, MEDICAL records, DESCRIPTIVE statistics, DEOXY sugars, COMPUTED tomography, TUMOR markers, PROGRESSION-free survival, PREDICTION models, IMMUNOTHERAPY, LONGITUDINAL method, OVERALL survival, PROPORTIONAL hazards models
Abstract: Simple Summary: Chemotherapy with immune checkpoint inhibitors is the new standard of care for first-line systemic therapy in extensive small-cell lung cancer. The identification of biomarkers for patients that are likely or not likely to respond to such therapy is critical. We aimed at determining whether imaging could help to predict outcomes among these patients. We showed that the total metabolic tumor burden, extracted from pre-treatment 18-FDG PET/CT imaging, may be a useful biomarker associated with survival. Finally, we think that this result should be taken into account in clinical trials, and that it might need further validation through large, independent, and prospective cohorts. Background: We aimed to evaluate the prognostic value of imaging biomarkers on 18F-FDG PET/CT in extensive-stage small-cell lung cancer (ES-SCLC) patients undergoing first-line chemo-immunotherapy. Methods: In this multicenter and retrospective study, we considered two cohorts, depending on the type of first-line therapy: chemo-immunotherapy (CIT) versus chemotherapy alone (CT). All patients underwent baseline 18-FDG PET/CT before therapy between June 2016 and September 2021. We evaluated clinical, biological, and PET parameters, and used cutoffs from previously published studies or predictiveness curves to assess the association with progression-free survival (PFS) or overall survival (OS) with Cox prediction models. Results: Sixty-eight patients were included (CIT: CT) (36: 32 patients). The median PFS was 5.9:6.5 months, while the median OS was 12.1:9.8 months. dNLR (the derived neutrophils/(leucocytes-neutrophils) ratio) was an independent predictor of short PFS and OS in the two cohorts (p < 0.05). High total metabolic tumor volume (TMTVhigh if > 241 cm3) correlated with outcomes, but only in the CIT cohort (PFS for TMTVhigh in multivariable analysis: HR 2.5; 95%CI 1.1–5.9). Conclusion: Baseline 18F-FDG PET/CT using TMTV could help to predict worse outcomes for ES-SCLC patients undergoing first-line CIT. This suggests that baseline TMTV may be used to identify patients that are unlikely to benefit from CIT. [ABSTRACT FROM AUTHOR]
Copyright of Cancers is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Complementary Index
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
CustomLinks:
  – Url: https://resolver.ebsco.com/c/xy5jbn/result?sid=EBSCO:edb&genre=article&issn=20726694&ISBN=&volume=15&issue=8&date=20230415&spage=2223&pages=2223-2236&title=Cancers&atitle=Total%20Metabolic%20Tumor%20Volume%20on%2018F-FDG%20PET%2FCT%20Is%20a%20Useful%20Prognostic%20Biomarker%20for%20Patients%20with%20Extensive%20Small-Cell%20Lung%20Cancer%20Undergoing%20First-Line%20Chemo-Immunotherapy.&aulast=Grambow-Velilla%2C%20Julia&id=DOI:10.3390/cancers15082223
    Name: Full Text Finder (for New FTF UI) (s8985755)
    Category: fullText
    Text: Find It @ SCU Libraries
    MouseOverText: Find It @ SCU Libraries
Header DbId: edb
DbLabel: Complementary Index
An: 163389482
RelevancyScore: 965
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 965.41748046875
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Total Metabolic Tumor Volume on 18F-FDG PET/CT Is a Useful Prognostic Biomarker for Patients with Extensive Small-Cell Lung Cancer Undergoing First-Line Chemo-Immunotherapy.
– Name: Author
  Label: Authors
  Group: Au
  Data: &lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Grambow-Velilla%2C+Julia%22&quot;&gt;Grambow-Velilla, Julia&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Seban%2C+Romain-David%22&quot;&gt;Seban, Romain-David&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Chouahnia%2C+Kader%22&quot;&gt;Chouahnia, Kader&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Assi&#233;%2C+Jean-Baptiste%22&quot;&gt;Assi&#233;, Jean-Baptiste&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Champion%2C+Laurence%22&quot;&gt;Champion, Laurence&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Girard%2C+Nicolas%22&quot;&gt;Girard, Nicolas&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Bonardel%2C+Gerald%22&quot;&gt;Bonardel, Gerald&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Matton%2C+Lise%22&quot;&gt;Matton, Lise&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Soussan%2C+Michael%22&quot;&gt;Soussan, Michael&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Choua&#239;d%2C+Christos%22&quot;&gt;Choua&#239;d, Christos&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Duchemann%2C+Boris%22&quot;&gt;Duchemann, Boris&lt;/searchLink&gt;
– Name: TitleSource
  Label: Source
  Group: Src
  Data: Cancers; Apr2023, Vol. 15 Issue 8, p2223, 14p
– Name: Subject
  Label: Subject Terms
  Group: Su
  Data: &lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22LUNG+cancer%22&quot;&gt;LUNG cancer&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22CONFIDENCE+intervals%22&quot;&gt;CONFIDENCE intervals&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22CANCER+chemotherapy%22&quot;&gt;CANCER chemotherapy&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22ANTINEOPLASTIC+agents%22&quot;&gt;ANTINEOPLASTIC agents&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22RETROSPECTIVE+studies%22&quot;&gt;RETROSPECTIVE studies&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22ACQUISITION+of+data%22&quot;&gt;ACQUISITION of data&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22CANCER+patients%22&quot;&gt;CANCER patients&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22TREATMENT+effectiveness%22&quot;&gt;TREATMENT effectiveness&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22RADIOPHARMACEUTICALS%22&quot;&gt;RADIOPHARMACEUTICALS&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22POSITRON+emission+tomography%22&quot;&gt;POSITRON emission tomography&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22MEDICAL+records%22&quot;&gt;MEDICAL records&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22DESCRIPTIVE+statistics%22&quot;&gt;DESCRIPTIVE statistics&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22DEOXY+sugars%22&quot;&gt;DEOXY sugars&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22COMPUTED+tomography%22&quot;&gt;COMPUTED tomography&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22TUMOR+markers%22&quot;&gt;TUMOR markers&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22PROGRESSION-free+survival%22&quot;&gt;PROGRESSION-free survival&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22PREDICTION+models%22&quot;&gt;PREDICTION models&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22IMMUNOTHERAPY%22&quot;&gt;IMMUNOTHERAPY&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22LONGITUDINAL+method%22&quot;&gt;LONGITUDINAL method&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22OVERALL+survival%22&quot;&gt;OVERALL survival&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22PROPORTIONAL+hazards+models%22&quot;&gt;PROPORTIONAL hazards models&lt;/searchLink&gt;
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Simple Summary: Chemotherapy with immune checkpoint inhibitors is the new standard of care for first-line systemic therapy in extensive small-cell lung cancer. The identification of biomarkers for patients that are likely or not likely to respond to such therapy is critical. We aimed at determining whether imaging could help to predict outcomes among these patients. We showed that the total metabolic tumor burden, extracted from pre-treatment 18-FDG PET/CT imaging, may be a useful biomarker associated with survival. Finally, we think that this result should be taken into account in clinical trials, and that it might need further validation through large, independent, and prospective cohorts. Background: We aimed to evaluate the prognostic value of imaging biomarkers on 18F-FDG PET/CT in extensive-stage small-cell lung cancer (ES-SCLC) patients undergoing first-line chemo-immunotherapy. Methods: In this multicenter and retrospective study, we considered two cohorts, depending on the type of first-line therapy: chemo-immunotherapy (CIT) versus chemotherapy alone (CT). All patients underwent baseline 18-FDG PET/CT before therapy between June 2016 and September 2021. We evaluated clinical, biological, and PET parameters, and used cutoffs from previously published studies or predictiveness curves to assess the association with progression-free survival (PFS) or overall survival (OS) with Cox prediction models. Results: Sixty-eight patients were included (CIT: CT) (36: 32 patients). The median PFS was 5.9:6.5 months, while the median OS was 12.1:9.8 months. dNLR (the derived neutrophils/(leucocytes-neutrophils) ratio) was an independent predictor of short PFS and OS in the two cohorts (p &lt; 0.05). High total metabolic tumor volume (TMTV&lt;superscript&gt;high&lt;/superscript&gt; if &gt; 241 cm&lt;superscript&gt;3&lt;/superscript&gt;) correlated with outcomes, but only in the CIT cohort (PFS for TMTV&lt;superscript&gt;high&lt;/superscript&gt; in multivariable analysis: HR 2.5; 95%CI 1.1–5.9). Conclusion: Baseline 18F-FDG PET/CT using TMTV could help to predict worse outcomes for ES-SCLC patients undergoing first-line CIT. This suggests that baseline TMTV may be used to identify patients that are unlikely to benefit from CIT. [ABSTRACT FROM AUTHOR]
– Name: Abstract
  Label:
  Group: Ab
  Data: &lt;i&gt;Copyright of Cancers is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder&#39;s express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.&lt;/i&gt; (Copyright applies to all Abstracts.)
PLink https://login.libproxy.scu.edu/login?url=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=163389482
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3390/cancers15082223
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 14
        StartPage: 2223
    Subjects:
      – SubjectFull: LUNG cancer
        Type: general
      – SubjectFull: CONFIDENCE intervals
        Type: general
      – SubjectFull: CANCER chemotherapy
        Type: general
      – SubjectFull: ANTINEOPLASTIC agents
        Type: general
      – SubjectFull: RETROSPECTIVE studies
        Type: general
      – SubjectFull: ACQUISITION of data
        Type: general
      – SubjectFull: CANCER patients
        Type: general
      – SubjectFull: TREATMENT effectiveness
        Type: general
      – SubjectFull: RADIOPHARMACEUTICALS
        Type: general
      – SubjectFull: POSITRON emission tomography
        Type: general
      – SubjectFull: MEDICAL records
        Type: general
      – SubjectFull: DESCRIPTIVE statistics
        Type: general
      – SubjectFull: DEOXY sugars
        Type: general
      – SubjectFull: COMPUTED tomography
        Type: general
      – SubjectFull: TUMOR markers
        Type: general
      – SubjectFull: PROGRESSION-free survival
        Type: general
      – SubjectFull: PREDICTION models
        Type: general
      – SubjectFull: IMMUNOTHERAPY
        Type: general
      – SubjectFull: LONGITUDINAL method
        Type: general
      – SubjectFull: OVERALL survival
        Type: general
      – SubjectFull: PROPORTIONAL hazards models
        Type: general
    Titles:
      – TitleFull: Total Metabolic Tumor Volume on 18F-FDG PET/CT Is a Useful Prognostic Biomarker for Patients with Extensive Small-Cell Lung Cancer Undergoing First-Line Chemo-Immunotherapy.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Grambow-Velilla, Julia
      – PersonEntity:
          Name:
            NameFull: Seban, Romain-David
      – PersonEntity:
          Name:
            NameFull: Chouahnia, Kader
      – PersonEntity:
          Name:
            NameFull: Assié, Jean-Baptiste
      – PersonEntity:
          Name:
            NameFull: Champion, Laurence
      – PersonEntity:
          Name:
            NameFull: Girard, Nicolas
      – PersonEntity:
          Name:
            NameFull: Bonardel, Gerald
      – PersonEntity:
          Name:
            NameFull: Matton, Lise
      – PersonEntity:
          Name:
            NameFull: Soussan, Michael
      – PersonEntity:
          Name:
            NameFull: Chouaïd, Christos
      – PersonEntity:
          Name:
            NameFull: Duchemann, Boris
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 15
              M: 04
              Text: Apr2023
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-print
              Value: 20726694
          Numbering:
            – Type: volume
              Value: 15
            – Type: issue
              Value: 8
          Titles:
            – TitleFull: Cancers
              Type: main
ResultId 1